1. Home
  2. MLYS vs TNL Comparison

MLYS vs TNL Comparison

Compare MLYS & TNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • TNL
  • Stock Information
  • Founded
  • MLYS 2019
  • TNL 1990
  • Country
  • MLYS United States
  • TNL United States
  • Employees
  • MLYS N/A
  • TNL N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • TNL Hotels/Resorts
  • Sector
  • MLYS Health Care
  • TNL Consumer Discretionary
  • Exchange
  • MLYS Nasdaq
  • TNL Nasdaq
  • Market Cap
  • MLYS 3.1B
  • TNL 3.3B
  • IPO Year
  • MLYS 2023
  • TNL N/A
  • Fundamental
  • Price
  • MLYS $38.06
  • TNL $61.83
  • Analyst Decision
  • MLYS Strong Buy
  • TNL Buy
  • Analyst Count
  • MLYS 6
  • TNL 10
  • Target Price
  • MLYS $42.60
  • TNL $62.30
  • AVG Volume (30 Days)
  • MLYS 1.6M
  • TNL 600.9K
  • Earning Date
  • MLYS 11-10-2025
  • TNL 10-22-2025
  • Dividend Yield
  • MLYS N/A
  • TNL 3.62%
  • EPS Growth
  • MLYS N/A
  • TNL N/A
  • EPS
  • MLYS N/A
  • TNL 5.78
  • Revenue
  • MLYS N/A
  • TNL $3,915,000,000.00
  • Revenue This Year
  • MLYS N/A
  • TNL $4.17
  • Revenue Next Year
  • MLYS N/A
  • TNL $4.25
  • P/E Ratio
  • MLYS N/A
  • TNL $10.72
  • Revenue Growth
  • MLYS N/A
  • TNL 2.46
  • 52 Week Low
  • MLYS $8.24
  • TNL $37.77
  • 52 Week High
  • MLYS $41.09
  • TNL $64.12
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 62.11
  • TNL 54.90
  • Support Level
  • MLYS $37.32
  • TNL $58.91
  • Resistance Level
  • MLYS $40.51
  • TNL $61.06
  • Average True Range (ATR)
  • MLYS 2.09
  • TNL 1.23
  • MACD
  • MLYS -0.77
  • TNL -0.04
  • Stochastic Oscillator
  • MLYS 43.86
  • TNL 76.84

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About TNL Travel Leisure Co. Common Stock

Travel+Leisure Co is a membership and leisure travel company. It provides hospitality services and travel products. The company operates in the segments of Vacation Ownership, which is the key revenue-driving segment, develops, markets and sells vacation ownership interests (VOIs) to individual consumers, provides consumer financing in connection with the sale of VOIs, and provides property management services at resorts, and Travel and Membership which operates a variety of travel businesses, including three vacation exchange brands, a home exchange network, travel technology platforms, travel memberships, and direct-to-consumer rentals. The majority of the revenue is earned from the United States.

Share on Social Networks: